X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (628) 628
antisickling agents - therapeutic use (562) 562
hydroxyurea - therapeutic use (463) 463
anemia, sickle cell - drug therapy (430) 430
male (314) 314
female (307) 307
index medicus (307) 307
hydroxyurea (273) 273
hematology (254) 254
child (232) 232
sickle cell anemia (230) 230
adult (209) 209
anemia (200) 200
adolescent (194) 194
sickle cell disease (170) 170
anemia, sickle cell - blood (164) 164
anemia, sickle cell - complications (151) 151
children (140) 140
child, preschool (135) 135
disease (132) 132
anemia, sickle cell - therapy (100) 100
hydroxyurea - adverse effects (100) 100
antisickling agents - adverse effects (99) 99
middle aged (99) 99
antisickling agents - pharmacology (93) 93
hemoglobin (92) 92
treatment outcome (91) 91
pediatrics (86) 86
medicine, general & internal (84) 84
young adult (79) 79
anemia, sickle cell - physiopathology (78) 78
therapy (78) 78
article (76) 76
blood transfusion (71) 71
animals (66) 66
risk-factors (66) 66
infant (65) 65
anemia, sickle cell - genetics (63) 63
oncology (63) 63
antisickling agents - administration & dosage (61) 61
hydroxyurea - administration & dosage (54) 54
care and treatment (50) 50
fetal hemoglobin (50) 50
fetal hemoglobin - metabolism (49) 49
analysis (48) 48
hydroxyurea - pharmacology (48) 48
trial (48) 48
pharmacology & pharmacy (47) 47
abridged index medicus (46) 46
retrospective studies (46) 46
anemia, sickle cell - diagnosis (45) 45
stroke (45) 45
anemia, sickle cell - metabolism (44) 44
pain (43) 43
antisickling agents (42) 42
mortality (41) 41
fetal-hemoglobin (40) 40
anemia, sickle cell - pathology (39) 39
follow-up studies (39) 39
acute chest syndrome (38) 38
erythrocytes - drug effects (38) 38
aged (37) 37
hydroxycarbamide (37) 37
biochemistry & molecular biology (35) 35
hemoglobin, sickle - metabolism (35) 35
stroke - prevention & control (35) 35
erythrocytes (34) 34
stroke - etiology (34) 34
drug therapy (32) 32
prevention (32) 32
time factors (32) 32
blood (31) 31
hemoglobins - metabolism (31) 31
randomized controlled trials as topic (31) 31
beta-thalassemia - drug therapy (30) 30
double-blind method (30) 30
fetal hemoglobin - analysis (29) 29
hemic and lymphatic diseases (29) 29
hydroxyurea therapy (29) 29
pulmonary-hypertension (29) 29
research (29) 29
young-children (29) 29
anemia, sickle cell - epidemiology (28) 28
management (28) 28
risk factors (28) 28
sickle cell (28) 28
dose-response relationship, drug (27) 27
health aspects (27) 27
anemia, sickle cell - mortality (26) 26
cross-sectional studies (26) 26
mice (26) 26
morbidity (26) 26
medicine, research & experimental (25) 25
adults (24) 24
fetal hemoglobin - genetics (23) 23
hemolysis (23) 23
medicine (23) 23
nitric-oxide (23) 23
prospective studies (23) 23
erythrocytes - metabolism (22) 22
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9757, pp. 2018 - 2031
Summary Sickle-cell disease is one of the most common severe monogenic disorders in the world. Haemoglobin polymerisation, leading to erythrocyte rigidity and... 
Internal Medicine | FETAL-HEMOGLOBIN LEVELS | MEDICINE, GENERAL & INTERNAL | HOSPITAL ADMISSIONS | RISK-FACTORS | PULMONARY-HYPERTENSION | ACUTE CHEST SYNDROME | HYDROXYUREA THERAPY | NITRIC-OXIDE | ADHESION MOLECULES | ACUTE VASOOCCLUSIVE CRISIS | PLASMODIUM-FALCIPARUM MALARIA | Haplotypes | Antisickling Agents - therapeutic use | Acute Chest Syndrome - etiology | Acute Chest Syndrome - therapy | Humans | Pain Management | Hypertension, Pulmonary - therapy | Blood Transfusion | Anemia, Sickle Cell - epidemiology | Erythrocytes - pathology | Pain - etiology | Anemia, Sickle Cell - classification | Hemolysis | Severity of Illness Index | Gene Transfer Techniques | Iron Chelating Agents - therapeutic use | Disease Susceptibility | Anemia, Sickle Cell - complications | Africa | Hematopoietic Stem Cell Transplantation | Polymerization | Nervous System Diseases - therapy | Anemia, Sickle Cell - therapy | Heart Diseases - etiology | Mass Screening | Heart Diseases - therapy | Kidney Diseases - therapy | Nervous System Diseases - etiology | Hydroxyurea - therapeutic use | Anemia, Sickle Cell - blood | Anemia, Sickle Cell - diagnosis | Kidney Diseases - etiology | Hypertension, Pulmonary - etiology | Hematopoietic Stem Cells | Care and treatment | Sickle cell anemia | Hemoglobin | Development and progression | Diagnosis | Health aspects | Risk factors | Disease | Rodents | Nitric oxide | Mutation | Gene therapy | Epidemiology | Federal funding
Journal Article
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 03/2014, Volume 189, Issue 6, pp. 727 - 740
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10091, pp. 311 - 323
Summary Sickle cell disease is a common and life-threatening haematological disorder that affects millions of people worldwide. Abnormal sickle-shaped... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | PULMONARY-HYPERTENSION | CLINICAL-TRIAL | SUB-SAHARAN AFRICA | FETAL-HEMOGLOBIN | EARLY-CHILDHOOD MORTALITY | TRANSCRANIAL DOPPLER ULTRASONOGRAPHY | TRANSFUSION-TRANSMITTED INFECTIONS | IRON OVERLOAD | YOUNG-CHILDREN | Hemolysis | Antisickling Agents - therapeutic use | Pregnancy Complications, Hematologic - prevention & control | Stroke - prevention & control | Anemia, Sickle Cell - complications | Humans | Pregnancy | Anemia, Sickle Cell - therapy | Global Burden of Disease | Stem Cell Transplantation - methods | Stroke - etiology | Cerebrovascular Disorders - prevention & control | Point-of-Care Systems | Iron Overload - therapy | Female | Hydroxyurea - therapeutic use | Anemia, Sickle Cell - diagnosis | Chronic Disease | Early Diagnosis | Hemolytic Plaque Technique | Blood Transfusion - methods | Genetic Therapy - methods | Prevention | Transplantation | Diagnostic imaging | Sickle cell anemia | Mortality | Stem cells | Occlusion | Erythrocytes | Iron | Pain | Ischemia | Penicillin | Hemoglobin | Sickle cell disease | Genetic modification | Stroke | Hematology | Anemia | Vessels | Blood vessels | Medical screening | Disease control | Morbidity | Blood flow | Magnetic resonance imaging | Antibiotics | Medical prognosis | Diagnostic systems | Chelating agents | Gene therapy | Risk management
Journal Article
Blood, ISSN 0006-4971, 07/2010, Volume 115, Issue 26, pp. 5300 - 5311
Hydroxyurea has many characteristics of an ideal drug for sickle cell anemia (SCA) and provides therapeutic benefit through multiple mechanisms of action. Over... 
RIBONUCLEOTIDE REDUCTASE | FETAL HEMOGLOBIN PRODUCTION | RISK-FACTORS | F PRODUCTION | THERAPY | SC DISEASE | NITRIC-OXIDE | FUNCTIONAL-ANALYSIS | HUG-KIDS | HEMATOLOGY | CHILDREN | Antisickling Agents - therapeutic use | Humans | Adolescent | Hydroxyurea - therapeutic use | Anemia, Sickle Cell - drug therapy | Clinical Trials as Topic | Child | How I Treat
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10019, pp. 661 - 670
Journal Article
Blood, ISSN 0006-4971, 12/2013, Volume 122, Issue 24, pp. 3892 - 3898
Recurrent and unpredictable episodes of vaso-occlusion are the hallmark of sickle cell disease. Symptomatic management and prevention of these events using the... 
HEMOGLOBIN | ADHESION | ADHERENT LEUKOCYTES | DOUBLE-BLIND | MICE | PLACEBO-CONTROLLED TRIAL | ANEMIA | HEMATOLOGY | PHASE-I | TISSUE FACTOR | RED-CELL | 103 | Review
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9778, pp. 1663 - 1672
Journal Article